Junshi Biosciences and Antengene to Evaluate JS207 with ATG-037 in Combination Therapy

Junshi Biosciences and Antengene announced a strategic collaboration to evaluate the combination of JS207 (a PD-1/VEGF bispecific antibody) and ATG-037 (an oral CD73 inhibitor). Prior data presented at Antengene's R&D Day showed ATG-037 plus anti-PD-1 therapy produced responses in checkpoint inhibitor–resistant melanoma and NSCLC, with an acceptable safety profile reported.

Junshi Biosciences and Antengene announced a strategic collaboration to evaluate a combination of JS207, a PD-1/VEGF bispecific antibody, and ATG-037, an oral CD73 inhibitor. The announcement describes plans to study the two agents together as a combination therapy. ATG-037 has previously shown clinical activity in combination with anti-PD-1 therapy in patients with checkpoint inhibitor–resistant melanoma and non‑small cell lung cancer. Those clinical findings were presented at Antengene's R&D Day in November 2025 and come from the ongoing Phase 1/1b STAMINA-01 study. Reported clinical findings: - In the STAMINA-01 dataset, ATG-037 plus anti-PD-1 therapy achieved an objective response rate (ORR) of 33.3% and a disease control rate (DCR) of 100% in patients with CPI‑resistant melanoma. - The same dataset showed an ORR of 21.4% and a DCR of 71.4% in patients with CPI‑resistant non‑small cell lung cancer. - The data were generated in Australia in patients with checkpoint inhibitor–refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti‑PD‑1 therapies; more than 70% of melanoma patients were reported as refractory to both anti‑PD‑1 monoclonal antibodies and anti‑CTLA‑4 (ipilimumab). - Safety findings reported a favorable tolerability profile in combination treatment, with grade 3 or higher treatment‑related adverse events occurring in 7.9% of patients and no new or unexpected safety signals noted. - Responses included durable outcomes, including a patient with a complete response remaining on study for over three years and multiple patients with durations of response exceeding 12 months. Summary: The collaboration will evaluate JS207 combined with ATG-037, building on prior clinical data that reported activity and an acceptable safety profile for ATG-037 in combination with anti‑PD‑1 therapy. Details on study design, patient population, and timing were not provided. Undetermined at this time.